MAPT and tauopathy: Collectively, this study defines the PRMT3/H4R3me2a/miR‐448 axis as a critical regulatory pathway in tau hyperphosphorylation within PART, underscoring the potential of PRMT3 inhibition as a targeted therapeutic strategy for tauopathies.